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Background: Epithelioid hemangioendothelioma is a rare vascular tumor of borderline or low-grade malignancy.
The lungs and liver are the two common primary organs affected. Metastatic disease was reported in more than
100 cases in the literature. However, no firm conclusions can be determined for recommended treatment options.
Case presentation: The current case presents a patient with metastatic pulmonary epithelioid hemangioendothelioma
to the cervical and mediastinal lymph nodes, lungs and liver that has been treated with pazopanib for more than two
years with PET avid complete metabolic response in the mediastinum and lungs, and long-lasting stable disease. Target
therapies that block VEGFR have a logical base in this rare malignancy.
Conclusions: The current case is the first to report objective, long-lasting response to pazopanib.
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Pulmonary epithelioid hemangioendothelioma (PEH) was
first described by Dail et al. in 1983, who called it an intra-
vascular bronchioloalveolar tumor [1]. Development of im-
munohistochemical techniques confirmed its endothelial
lineage, and Wiess et al. subsequently suggested the current
name, “epithelioid hemangioendothelioma” [2]. Immuno-
histochemistry for PEH showed diffuse cytoplasmic staining
of the malignant cells, with some or all of the vascular-
endothelial markers (CD31, CD34 and factor VIII) [3].
Epithelioid hemangioendothelioma (EHE) is a rare vas-
cular tumor of borderline or low-grade malignancy. The
lungs and liver are the two common organs for primary
EHE, but it can spread through the bloodstream to other
sites, such as bone and soft tissue. According to a litera-
ture review, nearly 100 cases have been described,
mainly discussing a differential diagnosis [4]. The treat-
ment options in metastatic disease are not well* Correspondence: g_barsela@rambam.health.gov.il
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unless otherwise stated.established. The current case presents a patient with
metastatic PEH that was treated with pazopanib as first
line of treatment.Case presentation
In December 2011, a 62-year old woman was referred to
our Emergency Department with a history of progressive
chest pain in the preceding 3 months. She had no prior
medical history, was a non-smoker, and denied any
history of cardiovascular diseases. CT scan revealed
multiple nodules in both lungs up to 6 mm in diameter,
multiple cervical lymph nodes up to 10 mm, and unclear
lesions in the liver.
For pathological diagnosis, the patient underwent
thoracoscopic surgery with wedge resection of two le-
sions from the right lung. Immunohistochemical (IHC)
stains demonstrated positive staining for endothelial
markers CD31, CD34, FLI-1, and ERG, representing
epithelioid hemangioendothelioma. The stain for ERG is
shown in Fig. 1a. IHC was performed also for vascular
endothelial growth factor receptor 1 (VEGFR1), and was
found to be strongly positive (Fig. 1b).tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fig. 1 Immunohistochemical staining. a Immunostain for ERG, showing strong nuclear stain of the tumor cells. Original magnification × 100. b
Immunostain for VEGF-R1, also designated Fms-like tyrosine kinase 1 (Flt-1), shows strong cytoplasmic staining of tumor cells. Original magnification × 200
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evaluation of unclear liver lesions, 18F-FDG PET-CT
was performed and showed increased pathological up-
take of 18F-FDG in the pulmonary nodules, cervical and
mediastinal lymph nodes, and the liver (Fig. 2a, b).
Following the advanced disease shown by the PET-CT
and the patient’s dyspnea, treatment with pazopanib in
the standard dose of 800 mg orally once daily was
started in April 2012. The treatment was given for more
than 2 years without any side effects, except grade I fa-
tigue. Other treatment options, such as interferon-alpha
or chemotherapy, were discussed with the patient before
treatment but were postponed by the patient due to con-
cerns of possible side effects.
Since the disease had been initially demonstrated on
PET scan, FDG-PET-CT was performed again in February
2013 and demonstrated disappearance of the pathological
uptake in the mediastinal lymph nodes and in the lung
lesions, with reduced metabolic response in the liver
(Fig. 2c, d). The last FDG-PET-CT in June 2014 showed
stable disease, without changes compared to February 2013.Discussion
According to a literature review, only 108 cases of this rare
tumor involving the lungs have been published. The lar-
gest series of PEH published in 2006 contained 93 cases.
The authors found an average age of 40.1 ± 17.3 years,
with a female predominance of 73 %. Almost half the pa-
tients (49.5 %) were asymptomatic at diagnosis. Reported
symptoms were dyspnea and cough (18.3 % each), chest
pain (16 %), hemoptysis and weight loss (6.5 % each) [4].
Epithelioid hemangioendothelioma can be primary in
the lung or pleura, or it may arise in liver, soft tissue or
bone. The prognosis is very unpredictable, with life ex-
pectancy ranging from 1 to 15 years [5].The poor prognostic factors of PEH include the presence
of respiratory symptoms or pleural effusion at diagnosis,
extensive intravascular, endobronchial or interstitial tumor
spreading, hepatic metastases, peripheral lymphadenop-
athy, or the presence of spindle cells in the tumor [2].
However, the worst prognosis was for patients with pleural
effusion or hemoptysis, with a median survival of less than
1 year [4]. The current patient had several poor prognostic
factors (respiratory symptoms, hepatic metastases, and
peripheral lymphadenopathy).
There is no established standard treatment for PEH,
due to the rarity of the disease. Surgical resection should
be performed if possible. In asymptomatic patients with
diffuse lesions, watchful waiting is an acceptable option
[1, 6]. Radiotherapy is not effective in certain patients
due to the slow growth of the tumor cells, and chemo-
therapy appears to have little effect [7–9]. A few cases
reported response or stable disease following immuno-
therapy treatment with interferon alpha [10–14].
Although its etiology remains unknown, immunohisto-
chemical and electron microscopy studies have revealed
that PEH is of endothelial origin [3]. Lymphatic dissem-
ination is extremely rare, thus supporting the endothelial
origin of the tumor. Vascular endothelial growth factor
(VEGF) and the VEGF receptor were found on PEH
tumor cells [15, 16], suggesting that VEGF inhibitors
may be a potential treatment for PEH. In a review pub-
lished a few years ago, anti-angiogenesis agents in angio-
sarcoma and EHE are discussed but, except for specific
activating mutations in VEGFR2, which may be effectively
targeted by VEGFR TKIs in some angiosarcomas, the bio-
logical mechanisms underlying the activity of these agents
in angiosarcoma and EHE are poorly understood [17].
However two small phase II studies were performed with
anti-angiogenic drugs in EHE. In a study by Agulnik et al.,
testing the effect of bevacizumab alone in angiosarcoma
Fig. 2 18F-FDG PET-CT. a PET-CT (selected axial slice) performed at staging, demonstrates pathological FDG foci in a few lung nodules. b PET-CT
(selected coronal slice) performed at staging, demonstrates pathological FDG foci in mediastinal lymph nodes and the liver. Additional findings were
demonstrated in a few cervical lymph nodes (not shown). c PET-CT (selected axial slice) performed after treatment, demonstrates a few lung nodules
with no FDG uptake. d PET-CT (selected coronal slice) performed after treatment, demonstrates pathological FDG foci in the liver. No mediastinal
findings are shown
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partial response (PR) and four had stable disease (SD)
[18]. In a sub-group report of 15 patients with EHE who
were included in the phase II study of the French Sarcoma
group testing the effect of sorafenib in sarcoma patients,
only two had PR and five had SD [19].Pazopanib is a second-generation tyrosine kinase
inhibitor with highly selective activity against VEGFR,
PDGFR, and c-KIT, which has demonstrated significant
clinical benefit in a variety of malignancies, especially for
the treatment of metastatic renal cell carcinoma [20].
The PALETTE (Pazopanib Explored In Soft Tissue
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demonstrating the efficacy of this anti-angiogenic agent
in pretreated soft tissue sarcoma (STS) patients, and
10 % of the patients in the pazopanib group had low-
grade sarcomas [21].
In the current case, the patient is still on treatment
with pazopanib, with partial response after a few months
and prolonged stable disease for up to 24 months based on
follow-up with a CT-PET-FDG scan. Considering that
chemotherapy is generally ineffective in epithelioid heman-
gioendothelioma, angiogenesis inhibition is a reasonable
approach to manage patients with metastatic EHE.
In a literature review for PEH cases and different
target anti-angiogenetic medication, only eight patients
who received chemotherapy and bevacizumab were
found [6, 9, 15, 16, 22–24]. Those cases are summarized
in Table 1. Partial response was reported in one case
only, with the combination of paclitaxel and carboplatin
[22]. Other reports of target therapy treatment in this
entity were not found.
Although the mechanism of action of thalidomide
and its analog, lenalidomide, is not fully understood, they
are believed to have immunomodulatory as well as anti-
angiogenic properties that logically can fit the treatment ofTable 1 Summary of patients with epithelioid hemangioendotheliom
First author (ref) No.pts. Median age Ge
Gaur S [6] 1 35 M
Belmont [22] 1 41 M
Kim [15] 1 44 F
Lopes [16] 1 51 M
Mizota [23] 1 59 F
Ye [9] 1 44 F
Lazarus [24] 1 42 M
1 42 M
Salech [25] 1 40 F
Raphael et al. [26] 1 53 F
Kassam et al. [27] 1 13 F
Bolke et al. [28] 1 47 M
Mascarenhas et al. [29] 1 52 M
Pallotti et al. [31] 1 73 M
Sumrall et al. [30] 1 31 F
Agulnik et al. [18] 2 NA NA
1 NA NA
4 NA NA
Chevreau et al. [19] 5 NA NA
2 NA NA
8 NA NA
PR partial response, PD progressive disease, SD stable diseasethis rare malignancy. A PubMed search using “thalidomide”
and “hemangioendothelioma” identified five case reports
[25–29], while “lenalidomide” and “hemangioendothe-
lioma” identified only two case reports [30, 31]. However,
none of these had primary thoracic involvement. These
cases are also summarized in Table 1, which shows that
two cases had partial responses that lasted up to 9 years in
one case and another two patients had stable disease last-
ing up to 7 years.Conclusions
In conclusion, based on the presentation of VEGFR1in
pulmonary epithelioid hemangioendothelioma cells, tar-
get therapies that block VEGFR have a logical base in
this rare malignancy. The current case is the first to re-
port objective, long-lasting response to pazopanib.Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.a treated with anti-angiogenic therapy
nder Treatment medications Response
Bevacizumab, Nab-Paclitaxel SD
Bevacizumab, Carboplatin, Paclitaxel PR
Bevacizumab, Carboplatin, Paclitaxel PD
Bevacizumab, Carboplatin, Etoposide PD
Bevacizumab, Carboplatin, Paclitaxel PD
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